2025 article

Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice

Inna P Gan'shina, Елена Владимировна Артамонова, Ярослав Андреевич Жуликов, M. V. Koroleva, Lyudmila Zhukova, Daria Filonenko, Маргарита Витальевна Сухова, E. P. Anokhina, I. G. Aseeva, S. V. Averyanova, S. A. BOL'SHAKOVA, V. V. Vysockaja, Alexey E. Vasilyev, M. V. Volkonsky, Д. В. Воронин, Valkin Dl, Viktor E. Goldberg, E. A. Dudnikova, G. A. Dashyan, O. V. Zharkova, Ruslan A. Zukov, A. M. Ivanov, E. E. Kiseleva, Yu. V. Kostalanova, Oleg Igorevich Kaganov, D. G. Lazareva, O. A. Lyubimova, Igor Myslevtsev, Viktorya V. Mikhalyuk, H. M. Mezhidova, M. R. Mukhitova, Константин Викторович Меньшиков, A. V. Orlov, Svetlana A. Orlova, Nataliya O. Popova, Ekaterina V. Peganova, A. P. Pecheny, Natalia M. Rats, Е. И. Симолина, А. В. Султанбаев, Yu. E. Stepura, T. H. Temirsultanova, Инесса Станиславовна Усольцева, Oksana Shirokova, В. А. Шаталова, Mikhail V Shaidorov

0Citations signalées, ce qui n’est pas une note de qualité

21Institutions déclarées

3Pays d’affiliation déclarés

Rattachement africain : ru, cz, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Introduction. Advances in molecular biology and biotechnology have enhanced the understanding of triple-negative breast cancer (TNBC) biology and facilitated the identification of patient subgroups that may potentially benefit from novel therapeutic approaches. Objective. The aim of this study is to evaluate the efficacy of the combination of atezolizumab and nab-paclitaxel in patients with locallyadvanced/metastatic TNBC in real-world clinical practice in the Russian Federation. Methods. This retrospective multicenter study included 65 patients with metastatic TNBC who received the atezolizumab and nab-paclitaxel in the second line of treatment and patients with early progression following neoadjuvant/adjuvant chemotherapy (≤12 months, primary resistance population) from October 2019 to September 2023 in routine clinical practice. Results. At the median follow-up of 11.5 months the median progression-free survival (mPFS) was 11.43 months (95 % CI, 6.59–16.28) in the ITT population. There was only factor associated with worsened mPFS – recurrence-free interval of ≤12 months following anthracycline/taxane-based neoadjuvant/adjuvant chemotherapy. mPFS was 15.8 months for primary metastatic or anthracycline/taxane-sensitive TNBC vs. 6.4 months for primary resistance population (OR 0.52, 95 % CI 0.54–0.97; p=0.03). A trend towards improved PFS was observed in the BRCA1/2 wt subgroup and patients with objective response. The mPFS for BRCA1/2 wt patients was 13.9 months vs. 5.6 months for BRCA1/2 mut patients (p=0.14). mPFS in patients with an objective response was 21.9 months vs 13.9 months in those without an objective response (p=0.63). Conclusions. This analysis represents the first multicenter study evaluating the efficacy of the combination of atezolizumab and nab-paclitaxel in real-world clinical practice in Russian population. The combination allows for an objective response rate of 20 % and mPFS of 11.43 months for patients as in the second line of treatment as with primary resistance.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice
Date Crossref: 03/07/2025
Éditeur: Alfmed LLC
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Pirogov Russian National Research Medical University N.N. Blokhin National Medical Research Center of Oncology pays non établi dans la notice
Université ou école supérieure
Moscow Clinical Scientific Center pays non établi dans la notice
Structure de recherche
State Healthcare Institution "Regional Clinical Oncological Dispensary" pays non établi dans la notice
Organisme public
Russian Scientific Center of Radiology and Surgical Technologies pays non établi dans la notice
Structure de recherche
Russian Academy of Sciences pays non établi dans la notice
Organisme public
Tomsk National Research Medical Center pays non établi dans la notice
Établissement de santé
Orenburg Regional Clinical Oncology Center pays non établi dans la notice
Établissement de santé
Moscow City Oncology Hospital №62 pays non établi dans la notice
Établissement de santé
First Pavlov State Medical University of St. Petersburg pays non établi dans la notice
Université ou école supérieure
Medical Technologies (Czechia) pays non établi dans la notice
Entreprise
Krasnoyarsk State Medical University Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky pays non établi dans la notice
Université ou école supérieure
Target (United States) pays non établi dans la notice
Entreprise

N.N. Blokhin National Medical Research Center of Oncology — Pirogov Russian National Research Medical University, Moscow Clinical Scientific Center et State Healthcare Institution "Regional Clinical Oncological Dispensary", avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies

Consulter la publication primaire Ouvrir le DOI